Developer docs
API playgroundTry for free, no card

Search company profiles

Algernon NeuroScience

Full company profile

uuid0004cwv

Namestring
Algernon NeuroScience
Legal namestring
Algernon NeuroScience
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT), as a sub-psychedelic neuroplasticity agent for acute ischemic stroke and traumatic brain injury (TBI). The drug candidate targets sigma-1 receptors and is designed to upregulate brain-derived neurotrophic factor (BDNF), with preclinical data showing a 40% increase in cortical neuron growth and near-full motor recovery in rat stroke models. A Phase 1 safety and tolerability trial in 29 healthy volunteers was completed at the Centre for Human Drug Research in the Netherlands in Q1 2024, meeting all primary endpoints, and a Phase 2a study in 40 ischemic stroke patients is planned for Q3 2025 at the National Institute of Hungary. A December 2024 clinical trial agreement with Yale University extends AP-188 into a third indication, major depressive disorder.

The company was founded in 2022 in Vancouver, Canada, as a wholly owned subsidiary of Grey Matters Health Inc. (formerly Algernon Pharmaceuticals). Capital formation has been executed through a Reg A+ offering of up to $10 million at a $10 million pre-money valuation, supplemented by a CAD $1.25 million private placement, a $500,000 strategic investment from American Molecular Imaging, and a $170,000 ValidCare tranche. The asset base is protected by a portfolio of pending patents covering novel DMT salt forms and methods of use, and the program is supported by an advisory board including Dr. Rick Strassman, Dr. David Nutt, Dr. Andrew Maas, and Dr. David Brody.

The business model is currently pre-revenue and contingent on eventual regulatory approval, out-licensing, or strategic acquisition of AP-188. Management has signaled an intent to pursue a NASDAQ uplisting following the Phase 2a read-out. The addressable market is framed at approximately $15 billion for stroke therapeutics by 2027 and $4.5 billion for TBI by 2026, with management of CEO Christopher J. Moreau and CFO James Kinley overseeing a team of 11–50. There are no current product sales, no licensing revenue, and no grant income disclosed; all funding to date has been dilutive equity capital.

Short descriptiontext

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous DMT formulation for treating acute ischemic stroke and traumatic brain injury, currently raising capital to fund Phase 2a trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroplasticity drug development, DMT clinical trials, stroke treatment research, traumatic brain injury therapy, psychedelic pharmaceutical research
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Neuropharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

Algernon NeuroScience is a clinical-stage pharmaceutical company developing DMT-based therapeutics for stroke and TBI. The company plans to advance through Phase 2a clinical trials with plans for potential NASDAQ IPO listing based on trial outcomes. Revenue would be generated through eventual drug approval, licensing agreements, or acquisition.

algernonneuroscience.com
2Regulation A+ Equity Offering
TypeSubscription Recurring
Description

The company filed a Form 1-A with the SEC under Tier II Regulation A+ offering, seeking to raise up to USD $5M (or up to $10M per company overview) for AGN Neuro by offering up to 37.5% of common shares. Capital raised will be used for research, development, and program management costs related to Phase 1 and Phase 2a DMT stroke studies.

algernonneuroscience.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT), administered at sub-psychedelic doses to promote neuroplasticity. Its pipeline targets acute ischemic stroke and traumatic brain injury (TBI), addressing conditions for which limited or no drug treatments exist. The company has completed a Phase 1 safety study in 29 healthy volunteers and is planning a Phase 2a ischemic stroke study in Hungary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40% increase in cortical neuron growth in preclinical studies at 30 nM DMT concentration
+4 more records
Product overview1 text field

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188 (DMT), a naturally occurring psychedelic compound, for two neurological indications: acute ischemic stroke and traumatic brain injury. The company has completed a Phase 1 safety study and is planning Phase 2a trials. The product works by increasing brain-derived neurotrophic factor (BDNF) and promoting neuroplasticity - the brain's ability to form and reorganize synaptic connections. The company's approach uses sub-psychedelic doses of DMT to avoid hallucinogenic effects while therapeutic. As a wholly owned subsidiary of Grey Matters Health Inc., it is also connected to NovaScan Neuroimaging Clinics, a network of brain PET scanning clinics for neuroimaging diagnostics.

Product and service2 records
1AP-188 (DMT) for Stroke
CategoryClinical-stage pharmaceutical - acute ischemic stroke
Description

Proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT) being developed for the treatment of acute ischemic stroke. The drug increases brain-derived neurotrophic factor (BDNF) and promotes neuroplasticity to facilitate recovery after stroke, administered at sub-psychedelic doses.

2AP-188 (DMT) for Traumatic Brain Injury
CategoryClinical-stage pharmaceutical - traumatic brain injury
Description

DMT being investigated as a potential treatment for traumatic brain injury (TBI). The therapy leverages the same neuroplasticity-promoting properties as the stroke program, addressing secondary brain injuries via neuroinflammation reduction and BDNF elevation, particularly for mild TBI patients with unresolved symptoms after 6 months.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1American Molecular Imaging
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Announced strategic business and USD $500K investment agreement with American Molecular Imaging. This partnership relates to the parent company Grey Matters Health's NovaScan Neuroimaging Clinics initiative for brain PET scanning.

algernonneuroscience.com
2Dr. Sándor Nardai / National Institute of Mental Health, Neurology and Neurosurgery
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Dr. Sándor Nardai, one of Europe's leading stroke experts and associate professor at Semmelweis University, will serve as principal investigator for the Phase 2a DMT stroke study in Hungary. Dr. Nardai conducted the groundbreaking rat stroke occlusion study published in 2020 that demonstrated DMT's therapeutic potential, showing that rats treated with sub-psychedelic DMT recovered almost full motor function and exhibited smaller infarct volumes.

algernonneuroscience.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Algernon Pharmaceuticals entered into a Clinical Trial Agreement with Yale University for a Phase 2 depression study using DMT. This partnership leverages Yale's expertise in psychiatric research and clinical trial infrastructure for exploring additional therapeutic applications of the company's DMT program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

The Centre for Human Drug Research in Leiden, Netherlands conducted Algernon's Phase 1 DMT clinical trial. The study assessed safety, tolerability, and pharmacokinetics of intravenous DMT administered as bolus followed by prolonged infusion in 29 healthy volunteers. The research institution has expertise in clinical pharmacology and has worked on multiple psychedelic drug studies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Canadian manufacturer with licenses to produce psychedelic compounds. Awarded DMT manufacturing contract for Algernon's stroke program. Produced clinical-grade cGMP DMT material for the company's Phase 1 clinical trials when other suppliers couldn't meet requirements.

6Dr. Rick Strassman
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Medical and Scientific Advisor and DMT expert. Dr. Strassman is Clinical Associate Professor of Psychiatry at UNM School of Medicine, author of 'DMT: The Spirit Molecule' (250,000 copies sold, 12 translations). His pioneering DMT research from 1990-1995 at University of New Mexico established foundational dosing protocols for Algernon's clinical program.

algernonneuroscience.com
7Dr. David Nutt
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Medical and Scientific Advisor and Neuropsychopharmacology expert. Professor at Imperial College London, former chair of UK Government's Foresight initiative on brain science, addiction and drugs. Advisor to the British National Formulary on psychiatry drugs. Published over 500 original research papers.

algernonneuroscience.com
8Dr. Andrew Maas
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

TBI Medical Advisor. Emeritus Professor of Neurosurgery at Antwerp University Hospital, past Chairman of Neurotraumatology Committee of World Federation of Neurosurgical Societies. Led the IMPACT study group awarded an NIH grant (2003-2011) and coordinates the CENTER-TBI European research project. Authored over 250 publications.

algernonneuroscience.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1MindMed
TypeDirect peer
Description

Clinical-stage psychedelic therapeutics company developing LSD (MM-120) and MDMA-based programs. Direct peer because it is a publicly traded clinical-stage psychedelic CNS company with comparable R&D-stage valuation dynamics, although its primary indications are anxiety/ADHD rather than stroke or TBI.

TypeDirect peer
Description

Pioneer in psilocybin therapy for treatment-resistant depression, with publicly disclosed clinical readouts and a comparable 'proprietary psychedelic formulation' IP model. Direct peer in clinical-stage CNS psychedelic drug development, despite working with a different molecule and indication.

TypeDirect peer
Description

Clinical-stage company developing mebufotenin (5-MeO-DMT, an inhaled DMT-class tryptamine) for treatment-resistant depression. The most directly comparable peer because it is developing a DMT-family tryptamine for CNS indication using a proprietary formulation, mirroring Algernon's AP-188 strategy.

4ATAI Life Sciences
TypeDirect peer
Description

Clinical-stage platform company with multiple psychedelic programs (including DMT-related assets through portfolio companies such as Viridia Life Sciences). Direct peer because of the multi-asset psychedelic platform structure and its exposure to CNS indications, including recent DMT-related pipeline activity.

TypeDirect peer
Description

Clinical-stage psychedelic CNS company (formerly Small Pharma) developing deuterated DMT (CYB004) for generalized anxiety disorder. Direct peer because it is developing a proprietary DMT-based formulation for a CNS indication through similar Phase 1/2 clinical development.

TypeBroad incumbent
Description

Commercial-stage CNS biopharma with FDA-approved neuroactive steroid Zurzuvae for postpartum depression and Zulresso. Broad incumbent providing a reference point for valuation, regulatory pathway, and commercial-scale CNS drug development, although Sage is more focused on depression than stroke/TBI.

TypeBroad incumbent
Description

Large neurology-focused biopharma with established CNS pipeline and commercialization infrastructure. Broad incumbent because it represents the type of larger partner or acquirer relevant to Algernon's CNS franchise, though Biogen operates at a vastly larger scale across neurodegenerative indications.

8H. Lundbeck
TypeBroad incumbent
Description

Specialty CNS biopharma with a portfolio of neurology and psychiatry products (e.g., vortioxetine, Rexulti). Broad incumbent that could plausibly acquire or partner a stroke/TBI asset post-Phase 2a, given its established CNS commercial footprint.

TypeEmerging player
Description

Emerging clinical-stage psychedelic CNS biotech developing intranasal and IV psychedelic formulations (now part of ATAI Life Sciences). Emerging player with partial overlap on psychedelic CNS drug delivery innovation, though focused on different indications.

TypeEmerging player
Description

Clinical-stage biotech developing RNA-targeted therapies against CXCL12 and other chemokines for stroke recovery and oncology. Emerging player with a relevant overlapping indication (post-stroke recovery) and similar clinical-stage development profile.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Algernon NeuroScience

Clinical-Stage Neuropharmaceuticalsalgernonneuroscience.com

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous DMT formulation for treating acute ischemic stroke and traumatic brain injury, currently raising capital to fund Phase 2a trials.

What Algernon NeuroScience does

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT), as a sub-psychedelic neuroplasticity agent for acute ischemic stroke and traumatic brain injury (TBI). The drug candidate targets sigma-1 receptors and is designed to upregulate brain-derived neurotrophic factor (BDNF), with preclinical data showing a 40% increase in cortical neuron growth and near-full motor recovery in rat stroke models. A Phase 1 safety and tolerability trial in 29 healthy volunteers was completed at the Centre for Human Drug Research in the Netherlands in Q1 2024, meeting all primary endpoints, and a Phase 2a study in 40 ischemic stroke patients is planned for Q3 2025 at the National Institute of Hungary. A December 2024 clinical trial agreement with Yale University extends AP-188 into a third indication, major depressive disorder.

The company was founded in 2022 in Vancouver, Canada, as a wholly owned subsidiary of Grey Matters Health Inc. (formerly Algernon Pharmaceuticals). Capital formation has been executed through a Reg A+ offering of up to $10 million at a $10 million pre-money valuation, supplemented by a CAD $1.25 million private placement, a $500,000 strategic investment from American Molecular Imaging, and a $170,000 ValidCare tranche. The asset base is protected by a portfolio of pending patents covering novel DMT salt forms and methods of use, and the program is supported by an advisory board including Dr. Rick Strassman, Dr. David Nutt, Dr. Andrew Maas, and Dr. David Brody.

The business model is currently pre-revenue and contingent on eventual regulatory approval, out-licensing, or strategic acquisition of AP-188. Management has signaled an intent to pursue a NASDAQ uplisting following the Phase 2a read-out. The addressable market is framed at approximately $15 billion for stroke therapeutics by 2027 and $4.5 billion for TBI by 2026, with management of CEO Christopher J. Moreau and CFO James Kinley overseeing a team of 11–50. There are no current product sales, no licensing revenue, and no grant income disclosed; all funding to date has been dilutive equity capital.

Algernon NeuroScience firmographics

Firmographics
Name
Algernon NeuroScience
Legal name
Algernon NeuroScience
Website
https://algernonneuroscience.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous DMT formulation for treating acute ischemic stroke and traumatic brain injury, currently raising capital to fund Phase 2a trials.
Ownership category
akta.pro rank

Algernon NeuroScience industry classification

Industry
Product category
Clinical-Stage Neuropharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neuroplasticity drug development
  • DMT clinical trials
  • Stroke treatment research
  • Traumatic brain injury therapy
  • Psychedelic pharmaceutical research

Where Algernon NeuroScience is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Algernon NeuroScience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: Algernon NeuroScience is a clinical-stage pharmaceutical company developing DMT-based therapeutics for stroke and TBI. The company plans to advance through Phase 2a clinical trials with plans for potential NASDAQ IPO listing based on trial outcomes. Revenue would be generated through eventual drug approval, licensing agreements, or acquisition.
  2. Regulation A+ Equity Offering: The company filed a Form 1-A with the SEC under Tier II Regulation A+ offering, seeking to raise up to USD $5M (or up to $10M per company overview) for AGN Neuro by offering up to 37.5% of common shares. Capital raised will be used for research, development, and program management costs related to Phase 1 and Phase 2a DMT stroke studies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Algernon NeuroScience product offering

Product offering

Core offering

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT), administered at sub-psychedelic doses to promote neuroplasticity. Its pipeline targets acute ischemic stroke and traumatic brain injury (TBI), addressing conditions for which limited or no drug treatments exist. The company has completed a Phase 1 safety study in 29 healthy volunteers and is planning a Phase 2a ischemic stroke study in Hungary.

Product overview

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188 (DMT), a naturally occurring psychedelic compound, for two neurological indications: acute ischemic stroke and traumatic brain injury. The company has completed a Phase 1 safety study and is planning Phase 2a trials. The product works by increasing brain-derived neurotrophic factor (BDNF) and promoting neuroplasticity - the brain's ability to form and reorganize synaptic connections. The company's approach uses sub-psychedelic doses of DMT to avoid hallucinogenic effects while therapeutic. As a wholly owned subsidiary of Grey Matters Health Inc., it is also connected to NovaScan Neuroimaging Clinics, a network of brain PET scanning clinics for neuroimaging diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

  • AP-188 (DMT) for Stroke Proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT) being developed for the treatment of acute ischemic stroke. The drug increases brain-derived neurotrophic factor (BDNF) and promotes neuroplasticity to facilitate recovery after stroke, administered at sub-psychedelic doses.
  • AP-188 (DMT) for Traumatic Brain Injury DMT being investigated as a potential treatment for traumatic brain injury (TBI). The therapy leverages the same neuroplasticity-promoting properties as the stroke program, addressing secondary brain injuries via neuroinflammation reduction and BDNF elevation, particularly for mild TBI patients with unresolved symptoms after 6 months.

Quantifiable outcome

  • 40% increase in cortical neuron growth in preclinical studies at 30 nM DMT concentration
  • +4 more outcomes

Companies that use Algernon NeuroScience

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Algernon NeuroScience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Algernon NeuroScience partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • American Molecular ImagingminorStrategic or Co-development Partner · 1 November 2025Announced strategic business and USD $500K investment agreement with American Molecular Imaging. This partnership relates to the parent company Grey Matters Health's NovaScan Neuroimaging Clinics initiative for brain PET scanning.
  • Dr. Sándor Nardai / National Institute of Mental Health, Neurology and NeurosurgerycoreStrategic or Co-development Partner · 1 January 2025Dr. Sándor Nardai, one of Europe's leading stroke experts and associate professor at Semmelweis University, will serve as principal investigator for the Phase 2a DMT stroke study in Hungary. Dr. Nardai conducted the groundbreaking rat stroke occlusion study published in 2020 that demonstrated DMT's therapeutic potential, showing that rats treated with sub-psychedelic DMT recovered almost full motor function and exhibited smaller infarct volumes.
  • Yale UniversitycoreStrategic or Co-development Partner · 1 December 2024Algernon Pharmaceuticals entered into a Clinical Trial Agreement with Yale University for a Phase 2 depression study using DMT. This partnership leverages Yale's expertise in psychiatric research and clinical trial infrastructure for exploring additional therapeutic applications of the company's DMT program.
  • Centre for Human Drug Research (CHDR)coreStrategic or Co-development Partner · 1 January 2022The Centre for Human Drug Research in Leiden, Netherlands conducted Algernon's Phase 1 DMT clinical trial. The study assessed safety, tolerability, and pharmacokinetics of intravenous DMT administered as bolus followed by prolonged infusion in 29 healthy volunteers. The research institution has expertise in clinical pharmacology and has worked on multiple psychedelic drug studies.
  • Dalton PharmacoreTechnology or Integration · 1 January 2021Canadian manufacturer with licenses to produce psychedelic compounds. Awarded DMT manufacturing contract for Algernon's stroke program. Produced clinical-grade cGMP DMT material for the company's Phase 1 clinical trials when other suppliers couldn't meet requirements.
  • Dr. Rick StrassmancoreStrategic or Co-development Partner · 1 January 2020Medical and Scientific Advisor and DMT expert. Dr. Strassman is Clinical Associate Professor of Psychiatry at UNM School of Medicine, author of 'DMT: The Spirit Molecule' (250,000 copies sold, 12 translations). His pioneering DMT research from 1990-1995 at University of New Mexico established foundational dosing protocols for Algernon's clinical program.
  • Dr. David NuttcoreStrategic or Co-development Partner · 1 January 2019Medical and Scientific Advisor and Neuropsychopharmacology expert. Professor at Imperial College London, former chair of UK Government's Foresight initiative on brain science, addiction and drugs. Advisor to the British National Formulary on psychiatry drugs. Published over 500 original research papers.
  • Dr. Andrew MaascoreStrategic or Co-development Partner · 1 January 2012TBI Medical Advisor. Emeritus Professor of Neurosurgery at Antwerp University Hospital, past Chairman of Neurotraumatology Committee of World Federation of Neurosurgical Societies. Led the IMPACT study group awarded an NIH grant (2003-2011) and coordinates the CENTER-TBI European research project. Authored over 250 publications.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Algernon NeuroScience competitors and assessment

Company assessment

Direct peers

  • MindMed: Clinical-stage psychedelic therapeutics company developing LSD (MM-120) and MDMA-based programs. Direct peer because it is a publicly traded clinical-stage psychedelic CNS company with comparable R&D-stage valuation dynamics, although its primary indications are anxiety/ADHD rather than stroke or TBI.
  • Compass Pathways: Pioneer in psilocybin therapy for treatment-resistant depression, with publicly disclosed clinical readouts and a comparable 'proprietary psychedelic formulation' IP model. Direct peer in clinical-stage CNS psychedelic drug development, despite working with a different molecule and indication.
  • GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT, an inhaled DMT-class tryptamine) for treatment-resistant depression. The most directly comparable peer because it is developing a DMT-family tryptamine for CNS indication using a proprietary formulation, mirroring Algernon's AP-188 strategy.
  • ATAI Life Sciences: Clinical-stage platform company with multiple psychedelic programs (including DMT-related assets through portfolio companies such as Viridia Life Sciences). Direct peer because of the multi-asset psychedelic platform structure and its exposure to CNS indications, including recent DMT-related pipeline activity.
  • Cybin: Clinical-stage psychedelic CNS company (formerly Small Pharma) developing deuterated DMT (CYB004) for generalized anxiety disorder. Direct peer because it is developing a proprietary DMT-based formulation for a CNS indication through similar Phase 1/2 clinical development.

Broad incumbents

  • Sage Therapeutics: Commercial-stage CNS biopharma with FDA-approved neuroactive steroid Zurzuvae for postpartum depression and Zulresso. Broad incumbent providing a reference point for valuation, regulatory pathway, and commercial-scale CNS drug development, although Sage is more focused on depression than stroke/TBI.
  • Biogen: Large neurology-focused biopharma with established CNS pipeline and commercialization infrastructure. Broad incumbent because it represents the type of larger partner or acquirer relevant to Algernon's CNS franchise, though Biogen operates at a vastly larger scale across neurodegenerative indications.
  • H. Lundbeck: Specialty CNS biopharma with a portfolio of neurology and psychiatry products (e.g., vortioxetine, Rexulti). Broad incumbent that could plausibly acquire or partner a stroke/TBI asset post-Phase 2a, given its established CNS commercial footprint.

Emerging players

  • Beckley Psytech: Emerging clinical-stage psychedelic CNS biotech developing intranasal and IV psychedelic formulations (now part of ATAI Life Sciences). Emerging player with partial overlap on psychedelic CNS drug delivery innovation, though focused on different indications.
  • Noxxon Pharma: Clinical-stage biotech developing RNA-targeted therapies against CXCL12 and other chemokines for stroke recovery and oncology. Emerging player with a relevant overlapping indication (post-stroke recovery) and similar clinical-stage development profile.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Algernon NeuroScience social profiles

Digital presence

Algernon NeuroScience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Algernon NeuroScience leadership team

Management profile

Number of profiles

Profiles9 records

Algernon NeuroScience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Algernon NeuroScience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Algernon NeuroScience

What does Algernon NeuroScience do?

Algernon NeuroScience is a clinical-stage pharmaceutical company developing AP-188, a proprietary intravenous formulation of N,N-Dimethyltryptamine (DMT), administered at sub-psychedelic doses to promote neuroplasticity. Its pipeline targets acute ischemic stroke and traumatic brain injury (TBI), addressing conditions for which limited or no drug treatments exist. The company has completed a Phase 1 safety study in 29 healthy volunteers and is planning a Phase 2a ischemic stroke study in Hungary.

Is Algernon NeuroScience a public or private company?

Algernon NeuroScience is a private company. It is classified as corporate owned and is currently operating.

When was Algernon NeuroScience founded?

Algernon NeuroScience was founded in 2022. It employs 1 to 10 people.

Where is Algernon NeuroScience based?

Algernon NeuroScience is headquartered in Vancouver, Canada, in the North America region.

How does Algernon NeuroScience make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are regulation A+ Equity Offering.

Who are Algernon NeuroScience's main competitors?

Direct peers on record are MindMed, Compass Pathways, GH Research, ATAI Life Sciences and Cybin. Broad incumbents are Sage Therapeutics, Biogen and H. Lundbeck. Emerging players are Beckley Psytech and Noxxon Pharma.

Does Algernon NeuroScience have an API?

No public API is recorded for Algernon NeuroScience.

What industry is Algernon NeuroScience in?

Algernon NeuroScience's product category is Clinical-Stage Neuropharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerAlgernon announces additional increase to private placement financingAlgernon Pharmaceuticals Inc. announced an additional increase to its private placement financing. The company focuses on developing repurposed therapeutic drugs for various medical conditions and is conducting clinical trials in Canada and Australia.The Streetwise ReportsBiotech Firm Gains Exclusive Alzheimer's Rights in U.S. & CanadaAlgernon Pharmaceuticals acquired NoBrainer Imaging Centers, gaining exclusive Alzheimer's franchise rights in the U.S. and Canada, with terms including 5.5 million shares and warrants. The company also announced a US$1 million private placement to fund its U.S. clinic launch in late 2025. The global Alzheimer's therapeutics and diagnostics market is projected to grow from US$9.7 billion in 2024 to US$19.6 billion by 2029.GlobeNewswireNetcapital to Host Planned Reg A Offering by Algernon NeuroScienceNetcapital Securities, a FINRA-registered broker-dealer, has been engaged by Algernon NeuroScience for its planned Regulation A offering. Algernon has filed a Form 1-A with the SEC, and intends to use proceeds for R&D. The offering has not yet been qualified or declared effective.GlobeNewswireAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A FinancingAlgernon NeuroScience appointed Netcapital Securities as its broker-dealer for a planned Regulation A offering, with the offering not yet qualified by the SEC. Proceeds will fund a Phase 2a DMT study of 40 stroke patients in Hungary in Q3 2025. The company also granted 1,405,000 RSUs and 1,000,000 stock options to executives.GlobeNewswireAlgernon NeuroScience Appoints Globally Recognized DMTAlgernon NeuroScience appointed Dr. Sándor Nardai as principal investigator for a Phase 2a DMT study of 40 stroke patients in Europe, expected to start enrolling in Q3 2025. The study will assess safety and secondary endpoints including lesion volume and motor function. DMT is a sub-psychedelic compound with prior preclinical stroke data.BioSpaceAlgernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity InvestmentAlgernon NeuroScience appointed Validcare as CRO for its Phase 2a DMT stroke trial in Europe, with enrollment expected in Q3 2025. Validcare will invest $170K in exchange for equity, completed in stages. The company also cancelled 684,000 vested stock options.GlobeNewswireAlgernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity InvestmentAlgernon NeuroScience appointed Validcare as CRO for its Phase 2a DMT stroke trial in Europe, with enrollment expected in Q3 2025. Validcare will invest $170K in exchange for equity, completed in stages. The company also cancelled 684,000 vested stock options.GlobeNewswireAlgernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity InvestmentAlgernon NeuroScience appointed Validcare as CRO for its Phase 2a DMT stroke trial in Europe, with enrollment expected in Q3 2025. Validcare will invest $170K in exchange for equity, completed in stages. The company also cancelled 684,000 vested stock options.BNNHow Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI TreatmentAlgernon Pharmaceuticals is advancing sub-psychedelic DMT for stroke and TBI treatment, with a Phase 2a study of 40 stroke patients planned for Q2 2025. The company has invested about $5 million and projects a NASDAQ IPO after positive data, targeting a $50–100 million valuation. Global stroke and TBI therapy markets are projected to reach $15 billion by 2027.